Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7685083 | 1.00 | ELANE (0.56) | ELANECHRNA7HTR3ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7654203 | 0.99 | ELANE (0.55) | ELANECHRNA7HTR3ALMNASMN1; SMN2 | |
| SCHEMBL2316032 | 0.96 | ELANE (0.60) | ELANECHRNA7HTR3ALMNASMN1; SMN2 | |
| SCHEMBL2313692 | 0.96 | ELANE (0.60) | ELANECHRNA7HTR3ALMNASMN1; SMN2 | |
| SCHEMBL7846334 | 0.89 | ELANE (0.67) | ELANECHRNA7HTR3ALMNASMN1; SMN2 | |
| SCHEMBL27479845 | 0.85 | LMNA (0.51) | ELANECHRNA7HTR3ALMNASMN1; SMN2 | |
| SCHEMBL6737804 | 0.84 | GABRP (0.50) | ELANESMN1; SMN2MAPTHCRTR1HCRTR2 | |
| SCHEMBL6738108 | 0.83 | GABRP (0.51) | ELANEHCRTR1HCRTR2GABRPGABRD | |
| SCHEMBL6737810 | 0.83 | PTGES (0.56) | HCRTR1HCRTR2GABRPGABRDGABRA1 | |
| SCHEMBL6734526 | 0.83 | ELANE (0.44) | ELANELMNASMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1611499-A | Heterocyclic compounds as inhibitors of rotamase enzymes | PFIZER (US) | 2005-05-04 | — | — | CN | disclosed |
| CN-1174978-C | Heterocyclic compounds useful as rotamase inhibitors | — | 2004-11-10 | — | — | CN | disclosed |
| CN-1511837-A | Intermediate for heterocyclic compound in preparing rotamase inhibitor | — | 2004-07-14 | — | — | CN | disclosed |
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6686357-B1 | BENZIMIDAZOLO-PIPERIDINE COMPOUND | PFIZER, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6562964-B1 | Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders | PFIZER INC | 2003-05-13 | — | — | US | disclosed |
| EP-1100797-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6509464-B1 | 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation | PFIZER INC | 2003-01-21 | — | — | US | disclosed |
| US-6495549-B1 | 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE | PFIZER INC | 2002-12-17 | — | — | US | disclosed |
| EP-1098894-B1 | FKBP INHIBITORS | PFIZER LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-6372736-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| CN-1315951-A | FKBP inhibitors | PFIZER LTD (US) | 2001-10-03 | — | — | CN | disclosed |
| CN-1310718-A | Heterocyclic compounds useful as rotamase inhibitors | PFIZER LTD (US) | 2001-08-29 | — | — | CN | disclosed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | disclosed |
| EP-1098894-A1 | FKBP INHIBITORS | Pfizer Limited (GB) | 2001-05-16 | — | — | EP | disclosed |
| US-6166011-A | FKBP inhibitors | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000005231-A1 | FKBP INHIBITORS | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | FKBP1A, FKBP4, FKBP1B | ELANE 4209/4885CHRNA7 2420/4885HTR3A 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.